Sorry, the video is currently unavailable.
The European Society of Cardiology 2020 virtual congress included three studies that examined the role of colchicine, a gout medication, in treating coronary artery disease. Drs. Ron Waksman and Spencer King discuss these and whether now, with two trials indicating that colchicine may be effective in treating CAD being released within the last year, cardiologists should start using this medication more widely. One question they ponder: Where does colchicine fit into the armamentarium of therapies, including statins, PCSK9 inhibitors, fish oil, and Lp(a)? Another question that those creating treatment guidelines should consider: What patients benefit the most from which therapies?